Aptose Biosciences Inc

Aptose Biosciences — Investor Presentation (July 2018)

30 slides from Aptose Biosciences's investor presentation, Jul 9, 2018

  1. Slide 1: Corporate Presentation July 09, 2018

    CORPORATE PRESENTATION JULY 09, 2018 NASDAQ: APTO TSX: APS

  2. Slide 2: Disclaimer and forward-looking statements

    2 This presentation does not, and is not intended to, constitute or form part of, and should not be construed as, an offer or invitation for the sale or purchase of, or a solicitation of an offer to purchase, subscribe for or otherwise acquire, any securities, businesses and/or assets of any entity,

  3. Slide 3: Aptose Corporate Snapshot

    3 Aptose Corporate Snapshot Clinical stage company employing a mechanism - driven approach to deliver safer, targeted, first - in - class cancer drugs Public Company NASDAQ: APTO / TSX: APS Shares Outs. (6/30/2018) Basic: 34.4 MM; FD: 38.8 MM No Warrants / No Preferred Stock / No Debt 3 Month ADTV ~

  4. Slide 4: Aptose Investment Highlights

    4 Aptose Investment Highlights Clinical stage biotechnology company developing first - in - class targeted agents to treat life - threatening hematological malignancies / orphan opportunities Two differentiated targeted agents with Strong IP Protection APTO - 253 : MYC Inhibitor - Only clinical stag

  5. Slide 5: Aptose Leadership Team

    5 Aptose Leadership Team – See www.aptose.com Dr. William G. Rice, PhD Chairman, President & CEO Achillion Pharmaceuticals: Founder, CEO, President, CSO, Director National Cancer Institute - FCRDC: Sr. Scientist, Drug Mechanism Lab Cylene Pharmaceuticals: Chairman, CEO, President, CSO Mr. Gregory Ch

  6. Slide 6: Aptose Scientific/Clinical Advisory Team

    6 Aptose Scientific/Clinical Advisory Team Dr. Brian J. Druker, MD Collaborator & Chair of SAB Key Role in Dev’t of Gleevec Member, National Academy of Sciences Winner of Karnofsky Award and Lasker “ America ’ s Nobel ” Award Leader of Inter - institutional Beat AML Initiative Dr. Michael Andreeff,

  7. Slide 7: Aptose Program Pipeline

    7 Aptose Program Pipeline DRUG TARGET INDICATION DISCOVERY PRE - CLINICAL PHASE 1 PHASE 2 APTO - 253 MYC AML / MDS CG - 806 Pan - FLT3 AML CG - 806 Pan - BTK (WT/C481S) Non - Covalent B Cell Cancers (CLL/MCL/DLBCL) APL - 581 BRD/Kinase Hematologic Malignancies (Program Partnered with Ohm/LALS) Compl

  8. Slide 8: APTO-253 Phase 1b Stage First-in-Class Inhibitor of MYC Expression

    APTO - 253 Phase 1b Stage First - in - Class Inhibitor of MYC Expression

  9. Slide 9: APTO-253 Phase 1b Clinical Development Plan

    9 APTO - 253 Phase 1b Clinical Development Plan Note: Phase 1b expansion cohorts and Phase 2 trials contingent on Phase 1b outcomes R/R AML and High Risk MDS • Planned up to 20 Patients • 1 o Endpts: MTD, DLT, RP2D • 2 o Endpts: PK, Biomarkers, Efficacy, Transfusions Single Agent Expansions MDS – Up

  10. Slide 10: APTO-253 Inhibits Expression of MYC

    10 APTO - 253 Inhibits Expression of MYC MYC Oncogene Regulates cell growth, proliferation, apoptosis - Dysregulated in numerous hematologic cancers , especially AML - Notoriously difficult to inhibit MYC e xpression/signaling APTO - 253 Value as Fresh Approach to Inhibit MYC - APTO - 253 is safe, c

  11. Slide 11: APTO-253 stabilizes G-quadruplex DNA, inhibits MYC expression

    11 APTO - 253 stabilizes G - quadruplex DNA, inhibits MYC expression and induces DNA damage in acute myeloid leukemia cells Andrea Local, Hongying Zhang, Khalid D Benbatoul, Peter Folger, Xia Sheng, Cheng - Yu Tsai, Stephen B. Howell, and William G. Rice AACR Journal: Molecular Cancer Therapeutics ,

  12. Slide 12: Aptose Program Pipeline

    12 Aptose Program Pipeline DRUG TARGET INDICATION DISCOVERY PRE - CLINICAL PHASE 1 PHASE 2 APTO - 253 MYC AML / MDS CG - 806 Pan - FLT3 AML CG - 806 Pan - BTK (WT/C481S) Non - Covalent B Cell Cancers (CLL/MCL/DLBCL) APL - 581 BRD/Kinase Hematologic Malignancies (Program Partnered with Ohm/LALS) Comp

  13. Slide 13: First-in-Class Pan-FLT3/Pan-BTK Multi-Cluster Kinase Inhibitor

    CG - 806 First - in - Class Pan - FLT3 / Pan - BTK “Multi - Cluster” Kinase Inhibitor

  14. Slide 14: Selectively and Potently Targets Clusters of Related Kinases

    • NOT a “Dirty Kinase Inhibitor” • Targets Clusters of Oncogenic Kinases operative in Cancers Derived from Bone Marrow • Selectivity for clusters linked to rigidity, functionalization, and “unique binding modes” 14 CG - 806 Selectively and Potently Targets “Clusters of Related Kinases” PDGFR TRKB AU

  15. Slide 15: Aptose Program Pipeline

    15 Aptose Program Pipeline DRUG TARGET INDICATION DISCOVERY PRE - CLINICAL PHASE 1 PHASE 2 APTO - 253 MYC AML / MDS CG - 806 Pan - FLT3 AML CG - 806 Pan - BTK (WT/C481S) Non - Covalent B Cell Cancers (CLL/MCL/DLBCL) APL - 581 BRD/Kinase Hematologic Malignancies (Program Partnered with Ohm/LALS) Comp

  16. Slide 16: For the Treatment of Acute Myeloid Leukemia (AML)

    16 CG - 806 For the Treatment of Acute Myeloid Leukemia (AML) Aggressive & Heterogeneous Cancer of Blood and Bone Marrow - 21,000 new cases estimated in US in 2016 and leading to 10,600 deaths 1 - FLT3 - ITD mutation is key driver in 25 - 35% of AML patients 2,3 (1) American Cancer Society : 2 Cance

  17. Slide 17: Only Known Pan-FLT3 Inhibitor for AML

    16 CG - 806: Only Known Pan - FLT3 Inhibitor for AML Plus, Targets Additional Rescue Pathways IC 50 ( nM ) Drug FLT3 - WT FLT3 - ITD CG - 806 (1) 8 0.8 Midostaurin (2) 11 11 Quizartinib (2) 4 8.8 (1) Reaction Biology Corp. (2) Blood. 2009 Oct 1; 114(14): 2984 – 2992 CG - 806 more potent FLT3 - ITD i

  18. Slide 18: Rapid and Sustained Tumor Eradication in Mouse Model of AML

    18 CG - 806 Induced Rapid and Sustained Tumor Eradication in Mouse Model of AML ORAL MV4 - 11 (FLT3 - ITD Driven AML) in Balb/c Mice EFFICACY 14 DAYS Treated Orally, Once Daily (QD) Dosing for 14 Days SAFETY Complete Tumor Elimination with No Observed Toxicity at These Doses

  19. Slide 19: Broad and Superior Potency Against AML Patient Samples

    19 CG - 806 Exerts Broad and Superior Potency Against AML Patient Samples CG - 806 Midostaurin Quizartinib Sorafenib Crenolanib Gilteritinib Patient Samples Heatmap of CG - 806 Versus Other FLT3 Inhibitors on Primary AML Samples 188 AML Patient Samples: Median IC 50 = 76nM Ex Vivo Drug Sensitivity A

  20. Slide 20: Oral, Small Molecule, Multi-Cluster Inhibitor: Potential Best-In-Class Agent for AML

    20 CG - 806 Oral, Small Molecule, Multi - Cluster Inhibitor: Potential Best - In - Class Agent for AML Superior Inhibition on FLT3 (WT / Mutant) Superior Inhibition on AML “Rescue” Pathways Superior Potency/Range on AML Cell Lines Superior Potency/Range on AML Patient Samples Combines Favorably Bcl

  21. Slide 21: Aptose Program Pipeline

    21 Aptose Program Pipeline DRUG TARGET INDICATION DISCOVERY PRE - CLINICAL PHASE 1 PHASE 2 APTO - 253 MYC AML / MDS CG - 806 Pan - FLT3 AML CG - 806 Pan - BTK (WT/C481S) Non - Covalent B Cell Cancers (CLL/MCL/DLBCL) APL - 581 BRD/Kinase Hematologic Malignancies (Program Partnered with Ohm/LALS) Comp

  22. Slide 22: Medical Need for Next Generation BTK Inhibitor

    22 Medical Need for Next Generation BTK Inhibitor Ibrutinib (Imbruvica ® ) is Current Standard of Care - $Multi - billion WW sales in 2017 (Bloomberg) Ibrutinib Shortcomings – Patients Discontinuing - 51% CLL Patients: D iscontinue treatment with ibrutinib after 3.4yrs (1) - 5 - 10% P atients: Resis

  23. Slide 23: Kinase inhibition profile versus ibrutinib

    23 Kinase CG - 806 IC50 ( nM ) BTK - WT 5.0 BTK - C481S 2.5 BTK - P190K 6.5 BTK - E41K 14.5 BLK 0.7 ITK 4.3 LCK 0.7 LYNA 2.0 LYNB 6.9 BMX/ETK 14.5 CG - 806 Potently Inhibits Kinases in the BTK Cluster but NOT Kinases Related to Ibrutinib Side Effects TEC EGFR ErbB2 ErbB4 CG - 806 >1,000 >1,000 >1,00

  24. Slide 24: Killing Potency Superior to Ibrutinib in Ba/F3 Cells Transfected with BTK

    24 CG - 806 Killing Potency Superior to Ibrutinib in Ba/F3 Cell Transfected with BTK -10 -8 -6 -4 -20 0 20 40 60 80 100 120 BTK Transfected Ba/F3 Cells Log [M] % I n h i b i t i o n None BTK FL BTK KD CG'806 Ibrutinib IC50 (nM) CG'806 Ibrutinib BTK FL 22.8 4555.0 BTK KD 23.2 1295.0 None 1001.0 > 10,

  25. Slide 25: Superior Killing Potency Compared to Ibrutinib Against Patient Samples

    CG - 806 Exerts Broad and Superior Killing Potency Compared to Ibrutinib Against Patient Samples 25 Presented at European Hematology Association 2018 CG - 806 , A NON - COVALENT PAN - FLT3/PAN - BTK INHIBITOR, EXHIBITS UNIQUE BINDING TO WILD TYPE AND C481S MUTANT BTK AND GREATER POTENCY THAN IBRUTIN

  26. Slide 26: Plus Venetoclax: Enhanced Killing of Bone Marrow Samples

    26 • CG - 806 and Venetoclax individually are highly active cancer agents • CG - 806 + Venetoclax Combination Studies • Enhanced ex vivo killing of patient bone marrow cells in most samples (green and orange spheres) • Suggests the combination of CG - 806 and Venetoclax may become a preferred drug c

  27. Slide 27: Differentiates from Other BTK Inhibitors

    27 CG - 806 Differentiates from Other BTK Inhibitors (Covalent and Non - Covalent) BTK IC 50 (nM) Key Off - Targets Agent Company Binding WT C481S ITK EGFR Ibrutinib (1) Abbvie Covalent 0.5 R 10.7 5.6 Acalabrutinib (2) AZ / Acerta Covalent 5.1 R >1000 >1000 CG - 806 APTOSE Non - Covalent 5.0 2.5 4.3

  28. Slide 28: Steps Toward the Clinic

    28 CG - 806: Steps Toward the Clinic x Completed manufacture of GLP API and formulation of drug product x Completed d ose range finding studies for pre - IND meeting with FDA » IND - enabling GLP toxicology studies in two species ongoing » Target IND Submission to FDA during 2018 » Planned Clinical

  29. Slide 29: Aptose Executive Summary

    29 Aptose Executive Summary Developing Highly Differentiated / Targeted Drugs for Blood Cancers APTO - 253 First - in - Class MYC Expression Inhibitor in Phase Ib for AML - Expect to commence screening and dosing of R/R - AML / hr - MDS patients soon - Potential to expand into B cell malignancy pati

  30. Slide 30: Thank You!

    Thank You! APTGSE BIOSCIENCES

Aptose Biosciences — Investor Presentation (July 2018) on 6ix